---
name: Merck KGaA
slug: merck-kgaa
site: cdmo
website_domain: biotechreality.com
summary: Recent coverage reports that Merck KGaA plans to sell its life science CDMO business to Lonza. The same coverage describes a new €300 million bioprocessing center in Daejeon, South Korea. Headquartered in Daejeon, South Korea.
tagline: 
founded_year: 
employee_count_band: 
employee_count_label: 
parent_name: 
parent_slug: 
hq_country: KR
tier2_domain_verified: false
updated_at: 2026-11-04T00:04:04.526Z
services_count: 0
modalities_count: 0
indications_count: 0
locations_count: 1
review_signal_gate: closed
generated_by: BioBM Editorial AI
---

# Merck KGaA

Listed on cdmo.directory.

## Summary

Recent coverage reports that Merck KGaA plans to sell its life science CDMO business to Lonza. The same coverage describes a new €300 million bioprocessing center in Daejeon, South Korea. Headquartered in Daejeon, South Korea.

## At a glance

- HQ country: KR

## Locations

- Daejeon Bioprocessing Center, Daejeon, South Korea

## Long description

## Overview

The source site (biotechreality.com) is a biopharma news and information publication. The excerpts contain headlines and summaries about Merck KGaA, not the company's own service descriptions.

## Reported activity

- **CDMO divestment:** A headline dated 3 November 2026 reports that Lonza is set to acquire Merck KGaA's life science CDMO business for mid-triple-digit million euros.
- **Daejeon bioprocessing center:** A headline dated 30 October 2026 reports the opening of a Merck bioprocessing center in Daejeon, South Korea, with a €300 million investment to expand Asia-Pacific biologics supply.

The excerpts do not establish Merck KGaA's current core business model, service lines, certifications, or headcount.

_Profile last updated: 2026-11-04T00:04:04.526Z. Profile facts may include AI-assisted enrichment._

Auto-generated by BioBM Editorial AI for machine-readable profile access.